Quiz: Partnering

Jan 7, 2016

We’re known for exceptional science and pioneering medical breakthroughs. We bring that same innovative and entrepreneurial spirit to our partnerships. Our goal with our partnerships is to create the most value for us, our partners and most importantly, for patients. Take this quiz to test your knowledge about partnering and learn more about some of our successful collaborations with companies and institutions from around the world.

1. How many of Genentech’s pipeline molecules and marketed products are a result of successful collaborations?1

10%
20%
35%
More than 50%
More than 50% of Genentech’s pipeline and marketed products are derived from successful collaborations with companies and institutions around the world. Good science doesn’t happen in a vacuum.

2. At what stage of product development do most Genentech partnering deals occur?2

After FDA approval
During Clinical Trials
Pre-Clinical stage
90% of Genentech partnering deals are made in the pre-clinical stage. Gaining access to early-stage assets with great science is our “sweet spot.”

3. Which of these partnering deals did Genentech sign in 2015?3

Immunocore
RQx Pharmaceutical
Almac Discovery
Afraxis
In June 2015, Genentech entered into a research licensing agreement with Almac Discovery to discover and develop small molecule inhibitors that target certain types of cancer.

4. Which deal provided an opportunity for Genentech to continue its 30 plus year commitment to breast cancer research?4

Acquisition of Seragon
Exclusive licensing agreement with NewLink Genetics
Collaboration with Xenon Pharmaceuticals
Research and technology deal with 23andMe
In 2014, Genentech obtained the rights to Seragon’s portfolio of investigational next-generation oral Selective Estrogen Receptor Degraders (SERDs) for the potential treatment of hormone receptor-positive breast cancer.

5. True or False? Partnering deals across different therapeutic areas should follow similar structures in order to be successful.1

False
True
To be successful, it’s important to be flexible. Our deal structures range from traditional milestone and royalty deals to acquisitions and options, and we often fund collaborative research. We’re committed to building collaborations that create the most value for each partner.

6. What type of deals does Genentech Partnering make?

Product Deals
Acquisitions
Academic & Research and Technology Collaborations
All of the above
We participate in a wide variety of collaborative partnerships including acquisitions, product deals, and collaborations with research and technology companies and academic research institutes.

7. In what year was the biotechnology industry created?5

1968
1976
1985
1987
In 1976, Dr. Herb Boyer, a biochemist, and Bob Swanson, a venture capitalist, met for a beer and later founded the first biotechnology company, Genentech. Collaboration has been part of Genentech’s DNA from the beginning.

8. At Genentech Partnering, what percentage of our business development team are scientists or doctors?6

25%
5%
50%
70%
70% of our business development team is made up of scientists or doctors.

9. Which of the following do we think is the most important economic factor for a biotech partnership?7

Cash
Liquidity
Value Creation
Biotech companies need a partner with a proven track record to develop, manufacture, and deliver medicines to patients in need.

10. True or False? Genentech Partnering only works with companies based in the United States?

False
True
Our overarching goal is to bring the best science and technologies in the world to Genentech. We follow the science regardless of where it takes us. We do collaborations around the world, not just in the United States.

References

Read More Stories

Tags

Read More Stories

Read about breakthrough science, the everyday people who make it happen, and the patients we serve.